According to the report published by the Market Research Store, global demand for the acute lymphoblastic testing market was estimated at approximately USD 3,106.8 Million in 2020 and is expected to generate revenue of around USD 4,900.1 Million by the end of 2026, growing at a CAGR of around 3.9% between 2021 and 2026.
Global Acute Lymphoblastic Testing Market: Overview
Acute Lymphoblastic leukemia is a type of cancer of the blood and bone marrow that affects white blood cells (WBCs) and it takes place when a bone marrow cell develops errors in its DNA. It is the most common childhood cancer. Also, both adults and children can be affected. Acute lymphoblastic leukemia is found rare, with around 790 people diagnosed with the condition each year in the UK. Moreover, a blood test is used to diagnose acute lymphocytic leukemia where they may also show the presence of blast cells — immature cells normally found in the bone marrow.
Global Acute Lymphoblastic Testing Market: Growth Factor
The increasing rate of the population suffering from acute lymphoblastic leukemia is anticipated to drive the growth of the acute lymphoblastic testing market. The major manufacturers work on the significant development of the healthcare industry which involves diagnostic innovations segment with the advanced product offerings and services. These impactful factors will help the acute lymphoblastic testing market growth in the forecast period. Also, the development of this market is owing to various factors such as escalating volume of cooperation being formulated between various market experts and leaders of diagnostic testing products.
| REPORT SNAPSHOT & REPORTING DATA TIMEFRAME |
| Parameter |
Details |
| Historical Date ( Actual Data) |
2016 - 2020 |
| Base Year Data |
2020 |
| Current Year Data |
2021 |
| Projected Data |
2021 - 2026 |
Global Acute Lymphoblastic Testing Market: Segmentation
The global acute lymphoblastic testing market is classified on the basis of leukemia type, product & service, technologies, and end-user industries. On the basis of Leukemia type, the acute lymphoblastic testing market is separated into Philadelphia chromosome, B-Cell, T-cell, and others. Based on the product and service, the acute lymphoblastic testing market is divided into services and assay kits. The acute lymphoblastic testing market based on the technology is segmented into PCR, IHC, NGS, cytogenetic, and others. Based on the end-user industry, the market for acute lymphoblastic testing can be segmented into clinical laboratories, hospitals, academic & research institutes, and others.
Global Acute Lymphoblastic Testing Market: Regional Analysis
The global acute lymphoblastic testing market examines and market size information is produced by country by leukemia type, product & service, technology, and end-user. The countries covering the market report are Canada, the U.S., and Mexico in North America, Germany, Netherlands, Italy, Spain, Turkey, Switzerland, France, U.K., Belgium, Russia, Rest of Europe in Europe, South Korea, India, Japan, China, Indonesia, Thailand, Philippines, Singapore, Malaysia, Australia, Rest of Asia-Pacific in the Asia-Pacific, Egypt, Saudi Arabia, Israel, South Africa, U.A.E., Rest of the Middle East and Africa as a part of the Middle East and Africa, Brazil, Argentina and Rest of South America as part of South America.
North America is dominating the acute lymphoblastic testing market due to its large-scale impact on the target disorder. Moreover, Asia-Pacific is predicted to observe the highest growth rate out of all the regions due to the increase in patients who are suffering from this disorder along with the focus of other key players to advance their prevalence in this region in the upcoming years.
Global Acute Lymphoblastic Testing Market: Competitive Players
The major key players in the acute lymphoblastic testing market involve Mayo Foundation for Medical Education and Research, DrLal Path Labs, Bio-Rad Lab, QIAGEN, Invivoscribe, Illumina, ArcherDx, ASURAGEN, Adaptive Biotechnologies, NeoGenomics Lab, Laboratory Corporation of America Holdings, and ARUP Lab.
For example, ArcherDx is a Boulder, Colorado-based biotechnology company and a manufacturer of sequencing assays purpose-built to identify mutations and gene fusions from clinical sample types. In 2020, AstraZeneca collaborated with ArcherDX, a genomic analysis company focused on precision oncology, to use personalized cancer monitoring to detect minimal residual disease (MRD) in patients with early-stage non-small-cell lung cancer (NSCLC).
Global Acute Lymphoblastic Testing Market: By Leukemia Type
- Philadelphia Chromosome
- B-Cell
- T-Cell
- Others
Global Acute Lymphoblastic Testing Market: By Product & Service
Global Acute Lymphoblastic Testing Market: By Technology
- PCR
- IHC
- NGS
- Cytogenetic
- Others
Global Acute Lymphoblastic Testing Market: By End-User
- Clinical Laboratories
- Hospitals
- Academic & Research Institutes
- Others
Global Acute Lymphoblastic Testing Market: Regional Segmentation Analysis
- North America
- Europe
- Germany
- The UK
- France
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Southeast Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Frequently Asked Questions
What are the key factors driving global acute lymphoblastic testing market expansion?
The increasing rate of the population suffering from acute lymphoblastic leukemia is anticipated to drive the growth of the acute lymphoblastic testing market. The major manufacturer’s works on the significant development of the healthcare industry which involves diagnostic innovations segment with the advanced product offerings and services. These are the impactful factors that will help the acute lymphoblastic testing market growth in the forecast period.
What will be the value of the acute lymphoblastic testing market during 2021- 2026?
The global demand for the lymphoblastic testing market was estimated at approximately USD 3,106.8 Million in 2020 and is expected to generate revenue of around USD 4,900.1 Million by the end of 2026, growing at a CAGR of around 3.9% between 2021 and 2026.
Which region will make notable contributions towards global acute lymphoblastic testing market revenue?
North America dominating the acute lymphoblastic testing market due to its largescale impact on the target disorder. Moreover, Asia-Pacific is predicted to observe the highest growth rate out of all the regions due to the increase in patients who are suffering from this disorder.
What are the key players leveraging acute lymphoblastic testing market growth?
The major key players in the acute lymphoblastic testing market involves NeoGenomics Laboratories, Inc., QIAGEN, Invivoscribe, Inc., Illumina, Inc., Bio-Rad Laboratories, Inc., ArcherDx, Inc., ARUP Laboratories, ASURAGEN, INC., Adaptive Biotechnologies, Mayo Foundation for Medical Education and Research, Laboratory Corporation of America Holdings, and DrLalPathLabs.
